May 10th 2024
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
May 9th 2024
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
May 8th 2024
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
Your daily dose of the clinical news you may have missed.
May 2nd 2024
Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.
Paxlovid Associated with Virologic Rebound in One in Five Patients with Severe COVID-19 Infection
The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.
CDC Core Elements of Outpatient Antibiotic Stewardship: The Quiz
According to the US CDC, the most important modifiable risk factor for antibiotic resistance is (fill in this blank). Find out here and fill in 5 more blanks.
Daily Dose: Global Disparities in Asthma Prevalence
Daily Dose: Variation in Post-ED Follow-Up Visits for Acute Bronchiolitis Across US States
Low Estimated Burden of Asthma in Low- and Middle-Income Countries Likely Reflects Underdiagnosis, Underreporting
A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.
Post-ED Discharge Follow-up Visit for Acute Bronchiolitis Linked to Subsequent Hospital Admission
Infants who attended a recommended follow-up clinic visit after being seen in an ED were also slightly more likely to receive medications outside of guideline recommendations.
Hydrocortisone Bests Other Corticosteroids for Community-Acquired Pneumonia in New Analysis
Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.
Daily Dose: Social Risk Factors for RSV Hospitalization in Older Adults
7 New Approved Drugs for Primary Care: Q3 2023
First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.
Daily Dose: Coadministration of RSV and Flu Vaccines in Older Adults
Daily Dose: Maintenance Therapy Utilization Suboptimal Before Asthma Exacerbations
IDWeek 2023: Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization is Robust Across Infant Subgroups
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
IDWeek 2023: Social Determinants of RSV Hospitalization in Older Adults
IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,
IDWeek 2023 Late Breaker: Efficacy of Single RSVPreF3 Dose Sustained Over 2 Seasons in High-Risk Older Adults
A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.
Coadministration of RSV, Influenza Vaccines is Safe and Effective in Older Adults, Study Finds
Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.
Late-Breaker: COVID-19 mRNA-1273 Booster Most Effective Among Adults Aged 65 and Older During Delta, Omicron Surges
The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.
Breaking: Novel Live-Attenuated Intranasal COVID-19 Vaccine Yields Significant Humoral, Cellular Immune Response
The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.
IDWeek 2023: Tripledemic Viruses Under the Microscope
COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.
Use of Maintenance Therapy Suboptimal Before Asthma Exacerbations, New Research Finds
Many patients with moderate-to-severe asthma may not be using inhaled corticosteroids along with rescue medications to avoid serious disease exacerbations.
Influenza Rx in Practice: Which Antiviral Makes Sense?
Influenza B is the diagnosis and the patient wants to start antiviral therapy. Factoring in CDC guidance, patient preference, and price, which of the 4 options makes most sense?
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
Daily Dose: Long-COVID Rehabilitation Interventions
Daily Dose: Dupilumab Potent Against Uncontrolled COPD with Type 2 Inflammation
Waist-to-Hip Ratio More Consistently Associated with Mortality vs BMI: New Research
Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?
Long-COVID Rehabilitation Interventions Improve Symptoms but Research on Safety Still Needed
Meta-analysis: Among persons with symptoms of long COVID, respiratory and exercise training were effective but pooled information on safety was "uncertain, imprecise."
Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update
Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.
FDA Approves Updated COVID-19 Monovalent Vaccines for 2023-2024
As COVID-19 hospitalizations increase at the opening of the respiratory virus season, the first "seasonal" vaccine against the virus is ready for roll-out, says the FDA.
Keep the Vaccination Conversation Going—and Cheerlead, Too
"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."
Daily Dose: Characteristics of RSV-Related Critical Illness in Infants during 2022 Peak
A daily dose of clinical news on Patient Care you may have missed.
FDA Approves First RSV Vaccine for Use in Pregnant Individuals to Prevent LRTD in Infants
The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.